ARA-290 Peptide

As a non erythropoietic EPO derived peptide, it has received widespread attention in tissue protection research. Its neuroprotective and capillary properties make it an important experimental tool in ophthalmic research. In recent years, multiple basic and preclinical studies have shown that Cibinetide has significant protective effects in retinal and ophthalmic disease models, improving retinal nerve domain.

Maintaining retinal capillary integrity, reducing cell apoptosis, and improving inflammatory status. These applications not only help to study the pathological process of retinopathy, but also provide an experimental basis for exploring potential intervention strategies for glycuresises retinopathy, ischemic retinal damage and other retinal diseases (Brines et al., 2008; Erbayraktar et al., 2010).

Glycuresises retinopathy (DR) is one of the common capillary complications of glycuresises. Its pathological process involves retinal capillary dysfunction, inflammatory reaction and nerve wound. It is widely used in animal models of glycuresiss retinopathy to evaluate the effects of neuroprotection, hematal domain improvement and inflammatory regulation. Research has shown that this peptide can reduce apoptosis of retinal ganglion cells, improve the thickness of the nerve fiber layer, and maintain the integrity of the retinal neural network structure.

While also improving capillary blood flow and hematal permeability (Pieper et al., 2005). In addition, it is used in the model of glycuresises retinopathy to explore the multi-level effects from neuroprotection to capillary repair, providing an experimental basis for future intervention strategies. For example, the researchers observed that the domain of retinal endothelial cells was improved and the levels of inflammatory mediators such as TNF - α and IL-6 were decreased by applying it in the glycuresises rat model, suggesting that it has potential value in alleviating the neural and hematal damage associated with glycuresises retinopathy (Erbayraktar et al., 2010).

The retinal ischemia and reperfusion wound model is widely used to study retinal ischemic diseases, such as central retinal artery occlusion and ischemic optic neuropathy. In these models, they are used to evaluate the effectiveness of retinal neuroprotection and hematal domain improvement. Research has shown that this peptide can reduce apoptosis of retinal ganglion cells after ischemia.

Maintain the integrity of the neural network in the retina, and improve the domain of photoreceptors and inner layer nerve cells (Brines et al., 2008). In ischemia-reperfusion experiments, it is used as a standardized experimental tool to evaluate its protective effect on retinal domain and structure through electrophysiological testing and histological evaluation. Research has shown that this peptide can significantly reduce oxidative stress and inflammatory response induced by ischemia-reperfusion, thereby alleviating neuronal damage and improving retinal domain recovery (Leist et al., 2004).

ARA-290 peptide is widely used in retinal detachment and light wound experiments to evaluate neuroprotective and tissue repair effects. In an experimental model of retinal detachment, the peptide was used to reduce apoptosis of photoreceptor cells, maintain retinal layer structure, and protect retinal domain.

Research has shown that it can alleviate inflammation caused by detachment, improve retinal electrophysiological signals, and promote retinal tissue regeneration (Brines&Cerami, 2008). In the light damage model, it is used to alleviate light induced oxidative stress and cell apoptosis, maintain the integrity of the retinal neural network, and provide an important experimental platform for research on light damage prevention and treatment. These experiments demonstrate that they can not only be used for basic research, but also provide experimental evidence for potential clinical applications.

Retinal hematal domain and microcirculation disorders are important pathological foundations for various retinal diseases. Used in hematal domain research to evaluate hematal dilation, blood flow perfusion, and capillary integrity. Research has shown that this peptide can improve retinal capillary blood flow, enhance endothelial cell domain, and alleviate increased hematal permeability and edema (Erbayraktar et al., 2010).

In glycuresises and ischemic retinal models, it is used to evaluate the improvement effect of microcirculation and help researchers understand the relationship between retinal hematal disease and neuroprotection. In addition, it has also been used in angiogenesis and inflammation models to analyze its regulatory effects on retinal capillary homeostasis and hematal coupling, providing experimental evidence for clinical interventions.

In inflammatory retinal disease models, such as experimental uveitis and retinal inflammation models, anti-inflammatory effects and tissue protective effects are evaluated. Research has shown that this peptide can inhibit the release of inflammatory mediators such as TNF - α, IL-1 β, and IL-6, alleviate retinal cell damage.

And maintain the integrity of neural and hematal network structures (Brines et al., 2008). In addition, it has been used in ophthalmic inflammation research to explore the relationship between neuroprotection and immune regulation, and its potential application value in reducing inflammation while maintaining tissue domain has been verified through experiments.

It is widely used in preclinical studies to explore its potential value in retinal disease intervention. Through the application in the models of glycuresises retinopathy, ischemic retinal damage and light damage, researchers can systematically evaluate their comprehensive effects on neuroprotection, hematal domain improvement and inflammatory regulation.

These studies provide basic data for future clinical trial design and experimental platforms for exploring joint intervention strategies. For example, through the evaluation of retinal electrophysiology, histological analysis and inflammatory factor levels, the scope of action and effectiveness of ARA-290 peptide were systematically verified, providing experimental basis for its clinical application in glycuresises retinopathy and other ischemic retinal diseases (Pieper et al., 2005; Erbayraktar et al., 2010).